infertility
Conditions
Brief summary
The primary efficacy endpoint is the number of good-quality blastocysts (GQB), according to the Istanbul Consensus Criteria. The primary efficacy endpoint is related to the primary trial objective.
Detailed description
Time of pronuclei appearance, Time of pronuclei disappearance, The total number of embryos, Time of division from 2 to 8 cells, Time of compactation, Time of morula, Time of cavitation, Time of full blastulation, Time of expanded blastocyst, Time of hatched blastocyst, Blastocyst formation rate, Cycle cancelation rate
Interventions
DRUGOvaleap 900 IU/1.5 mL solution for injection
DRUGUtrogestan 200 mg cápsulas vaginales blandas
DRUGOmifin 50 mg comprimidos
Sponsors
Santiago Dexeus Font Fundacio Privada
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint is the number of good-quality blastocysts (GQB), according to the Istanbul Consensus Criteria. The primary efficacy endpoint is related to the primary trial objective. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of pronuclei appearance, Time of pronuclei disappearance, The total number of embryos, Time of division from 2 to 8 cells, Time of compactation, Time of morula, Time of cavitation, Time of full blastulation, Time of expanded blastocyst, Time of hatched blastocyst, Blastocyst formation rate, Cycle cancelation rate | — |
Countries
Spain
Outcome results
None listed